Skip to content

Exclusive CEO Interviews

Archive

June 2026

3: Kim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026

June 2026

3: Jason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026

June 2026

3: Dimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026

June 2026

3: Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026

June 2026

2: Sean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026

June 2026

2: Augustin de Bettignies, Chief Business Officer, MPC Therapeutics | Onyx Live | ISCT Dublin 2026

June 2026

1: Stephen Sullivan, Founder & Managing Director, Lindville Bio | Onyx Live | ISCT Dublin 2026

June 2026

1: Jeff Galecke, Managing Partner, i5 BioPartners | Onyx Live | ISCT Dublin 2026

June 2026

1: Sven Kili, Partner, Saisei Ventures | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

30: Bruce Levine, Co-inventor of Kymriah, University of Pennsylvania | Onyx Live | ISCT Dublin 2026

May 2026

29: Miguel Forte, President, ISCT | Onyx Live | ISCT Dublin 2026

May 2026

28: Lisa Deschamps, CEO, AviadoBio | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

27: Marion Hitchcock, Managing Director, Gene & Cell Therapies Incubator Berlin | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

27: Faraz Ali, CEO, Tenaya Therapeutics | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

20: Bernd Mühlenweg, CBO/CFO, Cellbox Solutions | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

20: Sarmitha Sathiamoorthy, President & Founder, AspireBio Consulting | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

20: Alberto Santagostino, CEO & President, AGC Biologics | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

20: Ali Soleymannezhad, Chief Commercial Officer, Cellares | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Father Kevin FitzGerald, Professor of Medical Humanities, Creighton University | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Steffen Thirstrup, Chief Medical Officer, European Medicines Agency | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Josh Schroeder, Chief of Staff, CTI Clinical Trial and Consulting Services | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Devyn Smith, CEO, Arbor Biotechnologies | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Alexander Seyf, CEO, Autolomous | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Victor Levitsky, CSO, Circio Holding ASA | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

18: Lawrence Tallon, CEO, Medicines and Healthcare products Regulatory Agency | Onyx Live | Cell & Gene Meeting on the Med 2026

May 2026

14: eSpraye (Pulmonary fibrosis, Dry Powder) - Onyx Analyst

May 2026

3: Stephen Majors, Vice President, Global Communications and Investor Relations, Alliance for Regenerative Medicine | Onyx Live | Cell & Gene Meeting on the Med 2026

April 2026

30: Eric Schlumpf, President & CEO, Stuart Therapeutics | Onyx Live | JPM 2026

April 2026

30: Stuart Lowe, Head of Advanced Therapies, TTP | Onyx Live | Advanced Therapies 2026

April 2026

29: The sugar layer biotech forgot - and why Anomer Bio thinks small molecules can finally drug it

April 2026

29: Stuart Curbishley, Chief Development & Manufacturing Officer, adthera bio | Onyx Live | Advanced Therapies 2026

April 2026

28: Miguel Forte, President, International Society for Cell & Gene Therapy | Onyx Live | Advanced Therapies 2026

April 2026

28: Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting

April 2026

22: DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

April 2026

12: Alexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026

April 2026

12: Marinna Madrid, Co-Founder, Cellino | Onyx Live | JPM 2026

April 2026

6: Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)

April 2026

3: FDA approvals - March 2026

April 2026

3: Novartis to acquire Excellergy, adding Phase 1 anti-IgE program

April 2026

2: Novo Nordisk's Awiqli delivers the first once-weekly basal insulin for type 2 diabetes

April 2026

2: FDA approves Rocket's Kresladi as the first gene therapy for severe leukocyte adhesion deficiency-I

April 2026

2: Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines

March 2026

31: Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026

March 2026

27: Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026

March 2026

27: Merck to Acquire Terns, Adding TERN-701 to Hematology Pipeline

March 2026

26: Kali licenses KT501 to Sanofi in autoimmune disease deal

March 2026

26: Denali’s AVLAYAH wins FDA accelerated approval in Hunter syndrome

March 2026

26: FDA Clears Corcept’s Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

March 2026

25: Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026

March 2026

25: India semaglutide market sees new moves from Lupin, Zydus, and Sun Pharma

March 2026

24: FDA expands IMCIVREE label to acquired hypothalamic obesity as EMANATE misses primary endpoints

March 2026

24: Abbott completes Exact Sciences deal, expanding diagnostics portfolio in cancer screening

March 2026

24: Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026

March 2026

23: Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease

March 2026

23: Oryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative Disorders

March 2026

22: Mike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026

March 2026

20: Aldeyra receives FDA complete response letter for Reproxalap

March 2026

19: Johnson & Johnson’s ICOTYDE brings a new oral IL-23 option to plaque psoriasis

March 2026

19: FDA approves Alfasigma’s Lynavoy for primary biliary cholangitis

March 2026

19: Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

March 2026

18: Novartis expands Cosentyx label with FDA approval in adolescent Hidradenitis Suppurativa

March 2026

17: China approves commercial BCI system for cervical spinal cord injury patients

March 2026

17: Lilly escalates compounding challenge after finding impurity in Tirzepatide-B12 products

March 2026

13: Chris Hall, CEO, Personalis | Onyx Live | JPM 2026

March 2026

13: Bristol Myers Squibb’s Mezigdomide Delivers Progression-Free Survival Benefit in Phase 3 SUCCESSOR-2 Trial

March 2026

13: BioNTech sets leadership transition as Sahin and Türeci plan move to new mRNA company

March 2026

13: Vertex posts positive week 36 phase 3 IgAN data for Povetacicept

March 2026

12: Agilent Technologies targets pathology growth with $950 million Biocare Medical acquisition

March 2026

12: FDA updates biosimilar development guidance as review experience accumulates

March 2026

11: FDA approvals – February 2026

March 2026

10: Xenon’s azetukalner meets Phase 3 endpoint in treatment-resistant focal onset seizures

March 2026

6: Affinia cites low-dose engineered capsid strategy as AFTX-201 receives Fast Track

March 2026

5: Twenty-seven years to one drug: How failure defined Cytokinetics before Aficamten

March 2026

4: Slone Partners’ Leslie Loveless on the post-boom talent reset in biopharma

March 2026

4: Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

March 2026

4: Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

February 2026

27: A national prostate screening programme would do more than detect cancer

February 2026

27: FDA greenlights Ascendis’ once-weekly YUVIWEL to boost growth in children with achondroplasia

February 2026

25: FDA proposes “plausible mechanism” route for individualized ultra-rare disease drugs

February 2026

24: Immedica Pharma’s Loargys adds an enzyme-replacement entrant for ultra-rare ARG1-D–related hyperargininemia

February 2026

23: Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

February 2026

21: FDA approves Vanda’s Bysanti for schizophrenia and bipolar I manic or mixed episodes

February 2026

20: A world-expert in Stargardt disease has developed a pill to slow vision loss: why Tinlarebant could win FDA approval

February 2026

19: Moderna-FDA public dispute cools as Administration agrees to review amended mRNA flu vaccine application

February 2026

18: Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)

February 2026

18: Verily launches free version of its Pre Exchange and Workbench solutions, powering precision health AI and discovery

February 2026

18: Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

February 2026

18: Belite Bio concludes phase 3 Stargardt trials with nearly 40% retinal cell preservation

February 2026

17: Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

February 2026

15: How India is leading a cancer revolution

February 2026

13: Verily Pre is Now “Awardable” in DoW’s Tradewinds Solutions Marketplace

February 2026

12: Key risk statements from boxed warning on six menopausal HRT labels removed by FDA

February 2026

12: Acrotech Biopharma brings a new topical PDE4 option - Adquey - into a crowded eczema market.

February 2026

12: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

February 2026

12: Guardant publishes Phase III data on ctDNA detection of residual disease after colon cancer surgery

February 2026

12: FDA approves Novocure’s Optune Pax for locally advanced pancreatic cancer

February 2026

11: Cellares secures $257 million Series D to scale automated cell therapy manufacturing

February 2026

11: Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 2026

9: SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

February 2026

9: Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer